•
Mar 31, 2019

CRISPR Therapeutics Q1 2019 Earnings Report

Total Revenue
$328K
Previous year: $1.36M
-75.8%
EPS
-$0.93
Previous year: -$0.62
+50.0%
R&D Expenses
$33.8M
G&A Expenses
$14.9M
Gross Profit
-$28.5M
Previous year: -$18.2M
+57.1%
Cash and Equivalents
$438M
Previous year: $342M
+28.0%
Free Cash Flow
-$44.8M
Previous year: -$23.2M
+92.9%
Total Assets
$498M
Previous year: $374M
+33.0%

CRISPR Therapeutics

CRISPR Therapeutics

CRISPR Therapeutics Revenue by Segment